Pfizer and the Avon Foundation for Women announce $1 million grants program
- Details
- Category: Pfizer
Despite the high level of public attention devoted to breast cancer awareness, more than 60 percent of respondents in a new national survey commissioned by Pfizer Inc. say they know little to nothing about metastatic breast cancer.(1) The survey is the first of its kind to examine the general public's understanding of metastatic breast cancer, which affects up to 250,000 women and men in the U.S. today.(2)
Novartis launches 7-Day Challenge to 'Live Like You' enabling people with MS to better understand their lives with MS
- Details
- Category: Novartis
In support of World MS Day, Novartis announced today the launch of the 7-Day Challenge to Live Like You for people with MS. The 7-Day Challenge to Live Like You, one of the first integrations of emerging technological trends by a pharmaceutical company, is simple: using wearable technology or accessing personal online systems that people use on a daily basis, including calendars, social media channels and fitness trackers, people with MS are invited to track their activities for seven days and gain valuable insights into what works best for their lifestyle.
Pfizer brings frequent heartburn relief OTC with new Nexium® 24HR
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) has announced the introduction in the U.S. of over-the-counter (OTC) Nexium®24HR, making The Purple Pill® available for the treatment of frequent heartburn (two or more days a week) in adults (18 years and older). Heartburn affects more than 60 million men and women in the United States at least once a month with 15 million Americans suffering from it daily.(1)
Clarification regarding Pfizer statement
- Details
- Category: AstraZeneca
AstraZeneca PLC ("AstraZeneca") notes the announcement made by Pfizer Inc. ("Pfizer") dated 19 May 2014 seeking to clarify certain matters set out in its announcement on 18 May 2014 which set out its final proposal to AstraZeneca (the "Final Proposal Announcement"). Following some questions from shareholders, AstraZeneca wishes to make clear the following points:
AstraZeneca rejects final proposal from Pfizer
- Details
- Category: Financial
The Board of AstraZeneca PLC notes the announcement by Pfizer Inc. of its final proposal to combine the two companies. Leif Johansson, Chairman of AstraZeneca mentioned that the final proposal is a minor improvement which continues to fall short of the Board's view of value and has been rejected.
Abbott enhances its position in fast-growing Latin American market
- Details
- Category: Abbott
Abbott (NYSE: ABT) has announced a definitive agreement to acquire Latin American pharmaceutical company CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and further expanding Abbott's presence in fast-growing markets. Under the terms of the agreement, Abbott will acquire the holding company that indirectly owns approximately 73 percent of CFR Pharmaceuticals and will conduct a public cash tender offer for all of the outstanding shares of CFR.
MedImmune and Incyte announce collaboration on immuno-oncology combination clinical trial
- Details
- Category: AstraZeneca
AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into a clinical study collaboration with biopharmaceutical company Incyte Corporation. The Phase I/II oncology study will evaluate the efficacy and safety of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360.
More Pharma News ...
- Boehringer Ingelheim will make detailed clinical trial data available to the scientific community
- Bayer HealthCare extends access to clinical trial data
- Pfizer announcement and AstraZeneca statement
- More than 19,000 Novartis associates worldwide volunteer for local causes on Community Partnership Day
- Pfizer reports first-quarter 2014 results
- AstraZeneca Board rejects Pfizer proposal
- Pfizer sends letter to Rt Hon David Cameron MP regarding commitments if proposed combination with AstraZeneca is completed